Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Menglei MA"'
Autor:
Junfeng Li, Jianjie Li, Huifeng Hao, Fangliang Lu, Jia Wang, Menglei Ma, Bo Jia, Minglei Zhuo, Jingjing Wang, Yujia Chi, Xiaoyu Zhai, Yuyan Wang, Meina Wu, Tongtong An, Jun Zhao, Fan Yang, Ziping Wang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Early diagnosis of lung adenocarcinoma (LUAD), one of the most common types of lung cancer, is very important to improve the prognosis of patients. The current methods can’t meet the requirements of early diagnosis. There is a p
Externí odkaz:
https://doaj.org/article/4e503b5f1afd433b84022af7092f79b2
Autor:
Yifan Sun, Yuejiao Liu, Jianjie Li, Yafang Tan, Tongtong An, Minglei Zhuo, Zhiyuan Pan, Menglei Ma, Bo Jia, Hongwei Zhang, Ziping Wang, Ruifu Yang, Yujing Bi
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 3 (2023)
ABSTRACT Recently, microbiota dysbiosis in lung cancer has attracted immense attention. Studies on lung microbes are mostly based on sequencing, which has left the potentially functional bacteria with extremely low abundance uncovered. In this study,
Externí odkaz:
https://doaj.org/article/3fe0dc4c5c094d3fb74d00220629153a
Autor:
Jingjing WANG, Yujia CHI, Hanxiao CHEN, Bo JIA, Xiaoyu ZHAI, Menglei MA, Jianjie LI, Minglei ZHUO
Publikováno v:
Chinese Journal of Lung Cancer, Vol 25, Iss 7, Pp 493-500 (2022)
Background and objective Epidermal growth factor receptor (EGFR) and cellular-mesenchymal to epithelial transition factor (c-Met) are widely expressed on cancer cells. There is a synergistic effect of EGFR and HGF/c-Met pathways on proliferation, dow
Externí odkaz:
https://doaj.org/article/d0afc86697594f568dd80cfe4c70b963
Autor:
Bo Jia, Zhi Dong, Di Wu, Jun Zhao, Meina Wu, Tongtong An, Yuyan Wang, Minglei Zhuo, Jianjie Li, Yang Wang, Jie Zhang, Xinghui Zhao, Sheng Li, Junfeng Li, Menglei Ma, Chen Chen, Xue Yang, Jia Zhong, Hanxiao Chen, Jingjing Wang, Yujia Chi, Xiaoyu Zhai, Song Cui, Rong Zhang, Qingwei Ma, Jian Fang, Ziping Wang
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Th
Externí odkaz:
https://doaj.org/article/442dc4d633c04047b3e301b119b02ba9
Publikováno v:
International Journal of Electrochemical Science. 18:100095
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4632008782524e6a8ce27ba2726dee0
https://doi.org/10.1016/j.ijoes.2023.100095
https://doi.org/10.1016/j.ijoes.2023.100095
Autor:
Chen Chen, Minglei Zhuo, Di Wu, Yujia Chi, Sheng Li, Yuyan Wang, Xue Yang, Jingjing Wang, Zhi Dong, Rong Zhang, Meina Wu, Jia Zhong, Junfeng Li, Xiaoyu Zhai, Qingwei Ma, Hanxiao Chen, Jian Fang, Song Cui, Jie Zhang, Menglei Ma, Yang Wang, Tongtong An, Jianjie Li, Xinghui Zhao, Ziping Wang, Jun Zhao, Bo Jia
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-7 (2020)
Cancer Cell International
Cancer Cell International
Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aaa02a0414ed851e36f668d886cbcc1
https://doaj.org/article/442dc4d633c04047b3e301b119b02ba9
https://doaj.org/article/442dc4d633c04047b3e301b119b02ba9
Autor:
Jingjing Wang, Xiaoyu Zhai, Xiaoling Chen, Ziping Wang, Lingdong Kong, Xue Yang, Jun Zhao, Yujia Chi, Hanxiao Chen, Yuyan Wang, Minglei Zhuo, Guangming Tian, Bo Jia, Tongtong An, Jianjie Li, Yuling He, Meina Wu, Jieran Long, Xinghui Zhao, Junfeng Li, Di Wu, Luka Brcic, Zhi Dong, Sheng Li, Jian Fang, Menglei Ma
Publikováno v:
Transl Lung Cancer Res
Background Pemetrexed/platinum chemotherapy has been the standard chemotherapy regimen for lung adenocarcinoma patients, but the efficacy varies considerably. Methods To discover new serum biomarkers to predict the efficacy of pemetrexed/platinum che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::769e8ebaf4b69fe7c05b24d74add927e
https://europepmc.org/articles/PMC7947410/
https://europepmc.org/articles/PMC7947410/
Autor:
Jingjing WANG, Yujia CHI, Hanxiao CHEN, Bo JIA, Xiaoyu ZHAI, Menglei MA, Jianjie LI, Minglei ZHUO
Publikováno v:
Chinese Journal of Lung Cancer; Jul2022, Vol. 25 Issue 7, p493-500, 8p
Autor:
Bo Jia, Zhi Dong, Di Wu, Jun Zhao, Meina Wu, Tongtong An, Yuyan Wang, Minglei Zhuo, Jianjie Li, Yang Wang, Jie Zhang, Xinghui Zhao, Sheng Li, Junfeng Li, Menglei Ma, Chen Chen, Xue Yang, Jia Zhong, Hanxiao Chen, Jingjing Wang, Yujia Chi, Xiaoyu Zhai, Song Cui, Rong Zhang, Qingwei Ma, Jian Fang, Ziping Wang
Background: Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcome on pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98ea79cc7b7f1d597731eabf8b9d1207
https://doi.org/10.21203/rs.3.rs-41000/v2
https://doi.org/10.21203/rs.3.rs-41000/v2